Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
14
datasets available to search
ShareScore release 0.9.0
Dataset results
14 results for “access to medicines”
Interviews for New Business Models for Pharmaceutical Innovation and Access to Medicines - Rare Diseases
<p>These supplementary materials represent the partial dataset in the form of semi-structured interviews, collected and analyzed in the research article "Alternative innovation models of pharmaceutical development for rare disease drugs: how (and) do they work?: A qualitative study". This article is one of the outcomes of the "New Business Models for Pharmaceutical Innovation and Global Access to Medicines" research project, conducted at the Global Health Center, within the Geneva Graduate Institute. The dataset contains 10/11 interviews collected and used in this article, which are published with the informed consent of the interviewees.</p> <p>Details about the research project can be found at: <a href="https://www.graduateinstitute.ch/NBM">https://www.graduateinstitute.ch/NBM</a></p>
Interviews for New Business Models for Pharmaceutical Innovation and Access to Medicines - Case Study of the Oral Cholera Vaccine Development
<p>These supplementary materials represent the partial dataset in the form of semi-structured interviews, collected and analyzed in the research article "The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model". This article is one of the outcomes of the "New Business Models for Pharmaceutical Innovation and Global Access to Medicines" research project, conducted at the Global Health Center, within the Geneva Graduate Institute. The dataset contains 8/16 interviews collected and used in this article, which are published with the informed consent of the interviewees.</p>
Emergency Medicine Palliative Care Access
ClinicalTrials.gov study NCT03325985. IPD Sharing: YES. Countries: 1. Publications: 14.
Interviews for New Business Models for Pharmaceutical Innovation and Access to Medicines - Pandemic Preparedness
<p>These supplementary materials represent the partial dataset in the form of semi-structured interviews, collected and analyzed in the research article "Unlocking global access to medicines for pandemics: the potential and limits of alternative innovation models". This article is one of the outcomes of the "New Business Models for Pharmaceutical Innovation and Global Access to Medicines" research project, conducted at the Global Health Center, within the Geneva Graduate Institute. The dataset contains 8/11 interviews collected and used in this article, which are published with the informed consent of the interviewees.</p> <p>Details about the research project can be found at: <a href="https://www.graduateinstitute.ch/NBM">https://www.graduateinstitute.ch/NBM</a></p>
Interviews for New Business Models for Pharmaceutical Innovation and Access to Medicines - Neglected Diseases
<p>These supplementary materials represent the partial dataset in the form of semi-structured interviews, collected and analyzed in the research article "Alternative pharmaceutical innovation models for neglected diseases: How can they continue to thrive?". This article is one of the outcomes of the "New Business Models for Pharmaceutical Innovation and Global Access to Medicines" research project, conducted at the Global Health Center, within the Geneva Graduate Institute. The dataset contains 8/21 interviews collected and used in this article, which are published with the informed consent of the interviewees.</p> <p>Details about the research project can be found at: <a href="https://www.graduateinstitute.ch/NBM">https://www.graduateinstitute.ch/NBM</a></p>
Differential pricing of medicines to improve access to medicines for hypertension and diabetes control in Ghana: The Ghana Access and Affordability Program, a multi-center prospective trial
<p>Access to medicines for hypertension and diabetes mellitus (DM) management is challenging in resource-limited countries. We sought to assess whether differential pricing of medicines based on socio-economic status would improve affordability of antihypertensive and anti-diabetic medications. A quasi-experimental, prospective cohort study was implemented at five Ghanaian health facilities, using differentially priced medicines. </p>
Impact of national drug pricing policy 2018 on access to medicines in Lahore Division, Pakistan: A pre-post survey study using WHO/HAI methodology
<p><span><b>Objective: </b>To evaluate the impact of new national drug pricing policy (NDPP) 2018 on the access to medicines in terms of prices, availability, and affordability.<b> </b></span></p> <p><span><b>Design: </b>Two cross-sectional surveys were undertaken before and after the launch of NDPP 2018, using a modified WHO/HAI methodology.</span></p> <p><span><b>Setting: </b>Four districts of Lahore division, Pakistan. </span></p> <p><span><b>Participants: </b>16 public sector hospitals and 16 private sector retail pharmacies. </span></p> <p><span><b>Measures: </b>The pre- and post-survey data on prices and availability of Lowest Price Generics (LPGs) and Originator Brands (OBs) of 50 medicines were obtained by visiting the same public and private sector health facilities (n=32). Out of 50, 46 surveyed medicines were from National Essential Medicines List (NEML). Inflation-adjusted median unit prices (MUPs) and median price ratios (MPRs) from 2019 were used for price comparison. Affordability was calculated in terms of number of days' wages required to get a standard treatment by the lowest paid unskilled government worker.</span></p> <p><span><b>Results:</b> The overall mean percent availabilities remained poor in both years i.e. far less than 80%. In public sector, the mean percent availability of OBs improved from 6.8% to 33.1% whereas, in case of LPGs it was reduced from 35.1% to 9%. In private sector, the mean percent availability of both OBs and LPGs demonstrated slight improvements in 2019 i.e. 55.0% to 58.3% and 20.3% to 32.3%. The adjusted MUPs and MPRs of OBs significantly increased by a median of 4.29% (Wilcoxon test p=0.001, p=0.0001). Whereas, the adjusted MUPs and MPRs of LPGs were increased by a median of 15.7% (p=0.002, p=0.0002). Overall the affordability of many medicines for common ailments reduced significantly in 2019.</span></p> <p><span><b>Conclusion</b><b>s</b><b>: </b>The availability of medicines slightly improved, except in the case of LPGs which was reduced at public sector. The implementation of NDPP 2018 led to increase in drug prices, making the standard treatment for some of the most prevalent ailments unaffordable. So verily, the drug pricing policy must be reviewed to ensure access to essential medicines.</span></p>
Impact of national drug pricing policy 2018 on access to medicines in Lahore Division, Pakistan: A pre-post survey study using WHO/HAI methodology
Open the record for dataset details and reuse information.
Facilitated Access to Optimized Treatment and Clinical Follow-Up for Elderly Patients by the Internal Medicine Heart Failure Outpatient Clinic - a Randomized Multicenter Prospective Study
ClinicalTrials.gov study NCT07040995. IPD Sharing: UNDECIDED. Countries: 0. Publications: 14.
Overcoming Barriers to Accessing Genetic Medicine
ClinicalTrials.gov study NCT05064241. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
ClinicalTrials.gov study NCT04936399. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
ClinicalTrials.gov study NCT05203172. IPD Sharing: YES. Countries: 17. Publications: 0.
Efficacy of Flow Restrictors in Limiting Access of Liquid Medicines by Young Children
ClinicalTrials.gov study NCT06938620. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Open Access Status of the 20 Journals with the highest JIF-Scores within the Subject Category General & Internal Medicine
<p>An Overview on the twenty journals with the highest Journal Impact Factors within the Subject Category General & Internal Medicine and their status as Open Access or Closed Access Journals.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.